Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares fell 5.8% during mid-day trading on Friday . The company traded as low as $14.92 and last traded at $15.06. 3,920,610 shares changed hands during trading, a decline of 5% from the average session volume of 4,132,900 shares. The stock had previously closed at $15.98.

A number of research firms have issued reports on FOLD. BidaskClub lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Chardan Capital boosted their target price on shares of Amicus Therapeutics from $12.50 to $17.50 and gave the company a “buy” rating in a research note on Thursday, August 10th. Zacks Investment Research raised shares of Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. J P Morgan Chase & Co reissued an “overweight” rating on shares of Amicus Therapeutics in a research note on Wednesday. Finally, Robert W. Baird reissued an “outperform” rating and set a $18.00 target price (up from $16.00) on shares of Amicus Therapeutics in a research note on Wednesday. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Amicus Therapeutics presently has a consensus rating of “Buy” and an average target price of $18.07.

The company’s market capitalization is $2.48 billion. The firm has a 50 day moving average price of $14.11 and a 200 day moving average price of $10.59.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.03. The firm had revenue of $7.16 million during the quarter, compared to analysts’ expectations of $6.96 million. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. During the same quarter last year, the company posted ($0.40) EPS. On average, equities research analysts anticipate that Amicus Therapeutics, Inc. will post ($1.32) earnings per share for the current year.

In related news, major shareholder Life Sciences Maste Perceptive acquired 1,500,000 shares of the stock in a transaction on Thursday, July 13th. The stock was purchased at an average price of $12.25 per share, for a total transaction of $18,375,000.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 3.40% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of FOLD. Janus Henderson Group PLC acquired a new stake in Amicus Therapeutics in the 2nd quarter valued at about $70,762,000. Wellington Management Group LLP increased its position in Amicus Therapeutics by 358.4% in the 1st quarter. Wellington Management Group LLP now owns 5,341,132 shares of the biopharmaceutical company’s stock valued at $38,083,000 after acquiring an additional 4,175,995 shares in the last quarter. Morgan Stanley increased its position in Amicus Therapeutics by 99.4% in the 1st quarter. Morgan Stanley now owns 6,128,481 shares of the biopharmaceutical company’s stock valued at $43,696,000 after acquiring an additional 3,055,039 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in Amicus Therapeutics in the 1st quarter valued at about $21,394,000. Finally, Farallon Capital Management LLC acquired a new stake in Amicus Therapeutics in the 2nd quarter valued at about $30,210,000.

ILLEGAL ACTIVITY NOTICE: This report was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.thecerbatgem.com/2017/10/08/amicus-therapeutics-inc-fold-stock-price-down-5-8.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Receive News & Stock Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related stocks with our FREE daily email newsletter.